- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:30 | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | - | SEC Filings | ||
| 05.06. | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 27.05. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease | 513 | GlobeNewswire (Europe) | Investigational Oral Candidate JOTROL Addresses a Parkinson's Disease Market with No Current Disease-modifying Therapies Available Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences... ► Artikel lesen | |
| 27.05. | Jupiter Neurosciences: EPS verfehlt Schätzungen - Umsatz schlechter als erwartet | 2 | Investing.com Deutsch | ||
| JUPITER NEUROSCIENCES Aktie jetzt für 0€ handeln | |||||
| 26.05. | D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. in Connection with its ~$2 Million Registered Direct Offering | 404 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / May 26, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system... ► Artikel lesen | |
| 21.05. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering | 5 | GlobeNewswire (USA) | ||
| 20.05. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering | 4 | GlobeNewswire (USA) | ||
| 20.05. | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million | 1 | GlobeNewswire (USA) | ||
| 20.05. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech | 642 | GlobeNewswire (Europe) | Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May... ► Artikel lesen | |
| 14.05. | JUPITER NEUROSCIENCES, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.04. | Centri: Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14 | 488 | Newsfile | Jupiter, Florida--(Newsfile Corp. - April 13, 2026) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform... ► Artikel lesen | |
| 07.04. | Jupiter Neurosciences stärkt Beirat für Expansion im Consumer-Bereich | 4 | Investing.com Deutsch | ||
| 07.04. | Jupiter Neurosciences adds advisors for consumer product expansion | 1 | Investing.com | ||
| 07.04. | Jupiter Neurosciences verstärkt Beirat für Produktlinie Nugevia | 3 | Investing.com Deutsch | ||
| 07.04. | Jupiter Neurosciences adds advisors for consumer product line | 1 | Investing.com | ||
| 01.04. | JUPITER NEUROSCIENCES, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 01.04. | JUPITER NEUROSCIENCES, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 25.02. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago | 1 | GlobeNewswire (USA) | ||
| 23.02. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 108,48 | +0,63 % | Dividendenbekanntmachungen (15.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A&W FOOD SERVICES OF CANADA INC CA0002251027 0,48 CAD 0,2966 EUR AEGON LTD ADR US0076CA1045 0,2468 USD 0,2134 EUR AGROB IMMOBILIEN... ► Artikel lesen | |
| INNOCAN PHARMA | 1,680 | -12,04 % | InnoCan Pharma unter massivem Druck: Was die wenigsten Anleger auf dem Schirm haben - Was erfahrene Trader jetzt tun | ||
| IONIS PHARMACEUTICALS | 64,20 | 0,00 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 10,650 | +1,96 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA, Expanding Total Commercial Coverage to ~52 Million U.S. Lives | Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 million additional U.S. commercial lives (10% of the ~177 million commercial... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 196,70 | +0,67 % | AbCellera Biologics Inc.: Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies | The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises its option to develop... ► Artikel lesen | |
| JAGUAR HEALTH | 2,400 | +6,67 % | Jaguar Health, Inc.: Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program | Reminder: Lisa Conte, Jaguar's founder & CEO, to present on June 24, 2026 at the Life Sciences Virtual Investor Forum to provide updates on company's crofelemer development program for rare intestinal... ► Artikel lesen | |
| KALA BIO | 3,340 | -7,48 % | XFRA 27F: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILKALA BIO INC. O.N.... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 2,500 | +1,63 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update | NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results... ► Artikel lesen | |
| IRONWOOD PHARMACEUTICALS | 3,040 | -1,30 % | IRONWOOD PHARMACEUTICALS INC - 8-K, Current Report | ||
| GRACE THERAPEUTICS | 2,350 | -1,26 % | Grace Therapeutics, Inc.: Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update | Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 14,000 | +1,01 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| MINDWALK | 1,350 | +2,27 % | Highflyer der Zukunft - "Must Have" für ihr Biotech-Depot?! | ||
| INMED PHARMACEUTICALS | 1,250 | -1,57 % | InMed Pharmaceuticals: InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements | Vancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), today announce that it had received written notice from the Listing... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 2,450 | -3,16 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model | Encinitas, California--(Newsfile Corp. - June 18, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced preclinical data showing that KIO-300, part of the company's novel ion channel modulator... ► Artikel lesen | |
| LIPOCINE | 2,320 | -0,43 % | Lipocine Inc.: Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 | SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment... ► Artikel lesen |
Das Unternehmen JUPITER NEUROSCIENCES INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -3,36 % bei einem Aktienkurs von 0,230 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JUPITER NEUROSCIENCES INC finden Sie auf Wallstreet Online.